基于人工智能的合成CT在磁共振-only放疗中开发与临床实施的挑战与机遇
该立场文件由专家在2022年ESTRO物理研讨会上讨论合成CT(sCT)解决方案的临床整合过程及结果,聚焦sCT开发与调试,概述安全实施MRI-only放疗工作流的关键要素。
要点
- CE/FDA批准的sCT解决方案现已可用于盆腔、脑和头颈部。
- sCT广泛临床实施的主要挑战在于缺乏对sCT调试和质量保证的共识。
- 本文概述了安全实施MRI-only放疗工作流的关键要素。
核心结论
- sCT临床实施的主要挑战在于缺乏对sCT调试和质量保证的共识,导致不同医院间sCT方法存在差异。
- 本文聚焦sCT开发与调试方面,概述了安全实施MRI-only放疗工作流的关键要素。
研究设计与样本
- 专家在2022年ESTRO物理研讨会上讨论sCT解决方案的临床整合并报告过程及结果,形成本立场文件。
主要发现
- 从MRI生成的sCT可作为放疗计划CT的替代,从而消除多模态影像配对相关的配准不确定性,降低成本并减少患者辐射暴露。
- CE/FDA批准的sCT解决方案现已可用于盆腔、脑和头颈部,而更复杂的深度学习算法正在其他解剖部位进行研究。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Synthetic computed tomography (sCT) generated from magnetic resonance imaging (MRI) can serve as a substitute for planning CT in radiation therapy (RT), thereby removing registration uncertainties associated with multi-modality imaging pairing, reducing costs and patient radiation exposure. CE/FDA-approved sCT solutions are nowadays available for pelvis, brain, and head and neck, while more complex deep learning (DL) algorithms are under investigation for other anatomic sites. The main challenge in achieving a widespread clinical implementation of sCT lies in the absence of consensus on sCT commissioning and quality assurance (QA), resulting in variation of sCT approaches across different hospitals. To address this issue, a group of experts gathered at the ESTRO Physics Workshop 2022 to discuss the integration of sCT solutions into clinics and report the process and its outcomes. This position paper focuses on aspects of sCT development and commissioning, outlining key elements crucial for the safe implementation of an MRI-only RT workflow.
引用
- Villegas F, Dal Bello R, Alvarez-Andres E, et al. Challenges and opportunities in the development and clinical implementation of artificial intelligence based synthetic computed tomography for magnetic resonance only radiotherapy. Radiother Oncol. 2024. PMID: 38885905. doi:10.1016/j.radonc.2024.110387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。